Reference:
Speicher, D. J., Rose, J., Gutschi, L. M., Wiseman, D., & McKernan, K. (2023). DNA fragments detected in monovalent and bivalent Pfizer/BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada: Exploratory dose response relationship with serious adverse events. [Journal/Publisher].
Summary:
The study by Speicher et al. (2023) investigates residual DNA in Pfizer and Moderna COVID-19 vaccines distributed in Ontario, Canada. Using quantitative polymerase chain reaction (qPCR) and fluorometry, they found significant levels of plasmid DNA in both vaccine types, exceeding FDA and WHO guidelines. The analysis involved 27 vials from 12 unique lots, revealing a dose-response relationship between DNA levels and serious adverse events (SAEs). The residual DNA ranged from 0.01 to 4.27 ng/dose, with findings suggesting that the DNA was likely encapsulated within lipid nanoparticles, protecting it from degradation. The authors highlight the need for methodological consistency when interpreting DNA content and urge further investigation into vaccine safety, particularly regarding the potential implications of residual DNA on adverse reactions. The study calls for updated regulatory guidelines to reflect modern manufacturing processes and the efficiency of DNA transfection.